Paragraph IV Challenges
| Tradename | Dosage | Generic Name | NDA | ANDAs Submitted | 180 Day Exclusivity Status | Submissiondate |
|---|---|---|---|---|---|---|
| SPINRAZA | Intrathecal Solution | nusinersen sodium | 209531 | 1 | 2026-03-10 | |
| AUSTEDO XR | Extended-release Tablets | deutetrabenazine | 216354 | 1 | 2026-03-02 | |
| RINVOQ LQ | Oral Solution | upadacitinib | 218347 | 1 | 2026-03-02 | |
| PYRUKYND | Tablets | mitapivat sulfate | 216196 | 1 | 2026-02-17 | |
| EVRYSDI | Tablets | risdiplam | 219285 | 1 | 2026-02-17 | |
| MOTPOLY XR | Extended-release Capsules | lacosamide | 216185 | 1 | 2026-02-10 | |
| >Tradename | >Dosage | >Generic Name | >NDA | >ANDAs Submitted | >180 Day Exclusivity Status | >Submissiondate |
